Capture–recapture analysis to estimate the incidence of invasive meningococcal disease in Germany, 2003 by Schrauder, Annette et al.
Capture–recapture analysis to estimate the incidence of invasive
meningococcal disease in Germany, 2003
A. SCHRAUDER 1,2, H. CLAUS 1, J. ELIAS3, U. VOGEL 3, W. HAAS1
AND W. HELLENBRAND 1*
1 Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
2 Field Epidemiology Training Programme (FETP), Germany
3 National Reference Centre for Meningococci, Institute for Hygiene and Microbiology, Josef-Schneider-Strasse
2, 97080 Würzburg, Germany
(Accepted 26 July 2006; first published online 29 August 2006)
SUMMARY
The incidence of invasive meningococcal disease (IMD) in Germany in 2003 was estimated by
the two-source capture–recapture method. As a unique personal identifier was unavailable, cases
with IMD tested at the National Reference Centre for Meningococci (NRZM) were matched with
cases reported to the Robert Koch Institute (RKI) through the statutory surveillance system by
using demographic and disease-specific variables common to both datasets. The estimated overall
incidence was 1.1 IMD cases/100 000 inhabitants, with a sensitivity of ascertainment of 64.8%
for NRZM and 89.4% for RKI. Case-fatality rate was estimated at 8.8%. Adjustment for
heterogeneity of capture according to age, region and serogroup observed in the NRZM (but
not RKI) source had minimal effect on the estimated incidence. The IMD incidence estimated by
capture–recapture analysis is thus only slightly higher than through statutory surveillance data.
As a degree of positive dependence between the systems cannot be ruled out, this estimate may
still be an underestimate. However, under ascertainment appears insufficient to explain the low
incidence of IMD in Germany compared to other European countries.
INTRODUCTION
Capture–recapture analysis (CRA) is used to evaluate
the completeness of reporting to surveillance systems
and to refine incidence or prevalence estimates of
diseases derived from these systems [1–5].
Capture–recapture methodology, originally devel-
oped to estimate the size of animal populations, was
adapted for use in epidemiology in the late 1960s
[6, 7]. In zoology, a sample of animals is captured,
tagged, and released. Subsequently, a second sample
is captured and the proportion of recaptured, tagged
animals determined. This permits estimation of the
total population. Underlying this method is the
crucial assumption that the ratio of marked to un-
marked animals in the entire population is the same as
the ratio in the recaptured population due to complete
mixing and independent sampling. Applied to human
populations, persons are ‘captured’ by appearing on
the list of one source and ‘recaptured’ by reappearing
on one or more other lists of one or more other
sources [8]. Persons can be marked by unique per-
sonal identifiers such as name or health insurance
number or by surrogate markers such as age, sex and
date of birth [9].
In comparison to other European countries [10] the
incidence of invasive meningococcal disease (IMD)
in Germany is low, estimated by national surveillance
* Author for correspondence : W. Hellenbrand, M.D. (CDN),
M.P.H., Department of Infectious Disease Epidemiology, Robert
Koch Institute, Seestrasse 10, 13353 Berlin, Germany.
(Email : hellenbrandw@rki.de)
Epidemiol. Infect. (2007), 135, 657–664. f 2006 Cambridge University Press
doi:10.1017/S0950268806007151 Printed in the United Kingdom
data as 0.7–0.9 cases/100 000 inhabitants between
2001 and 2005 [11, 12]. As in most European countries
IMD due to serogroup B is most common, followed
by disease due to serogroup C.
In Germany, IMD has been a statutorily notifiable
disease since 2001 according to the Protection
Against Infection Act (Infektionsschutzgesetz, IfSG).
Physicians diagnosing meningococcal meningitis or
sepsis as well as laboratories identifying Neisseria
meningitidis from sterile sites are required to notify
cases to regional health authorities. All cases fulfilling
the case definition [13] are relayed to state health
authority level where further quality checks take
place, and from there to national level at the Robert
Koch Institute (RKI). The National Reference Centre
for Meningococci (NRZM), located at the Institute
for Hygiene and Microbiology at the University of
Würzburg in the state of Bavaria, receives patient
specimens from normally sterile sites and patho-
gen isolates from hospitals or laboratories located
throughout Germany. Laboratories are not legally
obliged to send specimens to NRZM for diagnosis,
but they are encouraged to do so in regular news-
letters and this service is provided free of charge.
So far, no attempts have been made to estimate
possible underreporting of IMD in Germany. Thus,
the objectives of our study were to assess the quality
of IMD data reported to the national surveillance
system and the NRZM, to determine the sensitivity
of both sources and to estimate serogroup-specific
incidence and mortality of IMD.
MATERIAL AND METHODS
Case definition
In this study cases were defined as patients with
laboratory confirmation of N. meningitidis from a
normally sterile site or as clinically compatible
cases with an epidemiological link to a laboratory-
confirmed case according to the national case
definition during 2003 in Germany. Laboratory
confirmation was defined as cultural isolation of
N. meningitidis, microscopic detection of Gram-
negative diplococci, detection of N. meningitidis
nucleic acid or the detection ofN. meningitidis antigen
(in cerebrospinal fluid only).
Description of datasets
In 2003, 779 cases fulfilling the above case definition
were reported to the RKI; four of these lacked
laboratory confirmation but were clinically compat-
ible and epidemiologically linked to a confirmed case.
Specimens from 565 patients were isolated and/or
typed at the NRZM in 2003.
Identifying matches
In accordance with the German Data Protection Act,
data were received at RKI in anonymized form.
Patients’ initials and the day of birth were removed
from the NRZM dataset prior to analysis at RKI.
Thus, the two data sources shared no common
identifier and the following five variables available in
both data sources were chosen to identify matching
cases : date of birth (month and year), sex, county of
residence, date of illness onset (day, month and year)
and serogroup. Three additional less specific variables
were used to exhaustively identify any remaining
potentially matching records : death of case (yes/no),
diagnostic material (serum, cerebrospinal fluid) and
clinical picture (meningitis, sepsis). All of these vari-
ables were identically available in both datasets with
one exception. While the NRZM dataset contained
the full five-digit postal code of the patient’s resi-
dence, the RKI dataset contained only the county of
residence. Thus the NRZM postal code was converted
to the corresponding county. As postal codes can
correspond to more than one county, 18 NRZM data
records had two possible counties.
To identify matching records, each RKI record
was compared with each NRZM record by means of
a difference function programmed in Microsoft1
Access, which initially included the five main match-
ing variables as defined above. The difference (delta)
between each of the matching variables (defined
above) derived from the two datasets in each of these
combined records was arbitrarily defined as 0 if the
variables were clearly identical, 1 if they were clearly
discrepant and as 0.5 if the respective variable was
missing in one of the two data records. The difference
between the ‘date of illness onset ’ was considered to
be 0 if the difference between the dates in both data-
sets was <7 days, 0.4 if the difference was between 7
and <14 days and 1 if it was o14 days. For cases in
the NRZM database whose postal code corresponded
to more than one county, we assigned a delta value of
0.1 if one of the counties matched the county in the
RKI database. All data-record pairs with minimal
differences between them (sum of the differences
f0.5) were accepted as being identical. For the
remaining cases, a difference function including the
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three additional variables (death of case, diagnostic
material, clinical picture) was implemented and all
data-record pairs with a sum of the differences of
f2.5 were considered as tentative matches. These
data-record pairs were then submitted to the regional
health offices after patients’ initials, postal code and
full date of birth were reinstated in the dataset by the
NRZM. Regional health office staff was asked to
look up additional available personal patient data in
order to determine whether these pairs were, in fact,
concordant.
All record pairs identified as matching were manu-
ally reviewed by one of the authors (A.S.).
Capture–recapture analysis
The two-sample capture–recapture method was used
to estimate total IMD incidence [14–16]. Cases from
a single underlying population ‘captured’ in one
dataset are ‘recaptured’ if they appear in a second
dataset. Certain underlying assumptions must hold
with this method.
The sources should be independent ; the population
should be closed; all identified cases should be true
cases ; for each source, the probability of capture
should be the same for all cases ; and all true matches
in the two sources must be identifiable.
A stratified analysis was carried out according
to factors that might affect the probability of capture
or be related to a possible positive dependency of
the two systems in order to check for an influence
of these factors on the overall incidence estimate of
IMD [17, 18]. The CRA was stratified by age (<5
years, 5–19 years, >19 years), by serogroup [limited
to the two predominant serogroups B and C due to
the large number of RKI cases with missing data
on serogroup (Fig.)], by region [Bavaria – where
the NRZM is located – and surrounding states
(Baden-Wurttemberg,Rhineland-Palatinate,Saarland,
Hesse, Thuringia, Saxony) vs. all remaining states
(North Rhine-Westphalia, Lower Saxony, Schleswig-
Holstein, Mecklenburg-Western Pomerania, Brand-
enburg, Berlin, Bremen, Saxony-Anhalt, Hamburg)],
and by vital status to check heterogeneity of capture.
As information on serogroup was considered ex-
tremely reliable and was never missing in the NRZM
dataset, the serogroup from the NRZM record was
assigned to the matching RKI record if the serogroup
was missing or discordant with NRZM findings
(39 pairs). If a case was reported to have died in one
system, its match in the other system was also con-
sidered a death (14 deaths from RKI source assigned
to matching NRZM cases not reported as dead).
Hospital discharge data
Hospital discharge data are available on an annual
basis from the Federal Statistical Office in Germany
[19]. However, as these are aggregated rather than
case-based data, they cannot serve as a third source
for CRA. Nonetheless, the number of cases dis-
charged with ICD-10 code A39 (meningococcal
infection) in 2003 was compared with the CRA esti-
mate obtained in our study. The ICD-10 code A39
includes the following clinical diagnoses: meningo-
coccal meningitis (A39.0), Waterhouse-Friderichsen
Syndrome (A39.1), acute meningococcaemia (A39.2),
chronic meningococcaemia (A39.3), meningococca-
emiaunspecified (A.39.4) ;meningococcalheartdisease
(A.39.5), other meningococcal infections (A.39.8) and
meningococcal infection, unspecified (A39.9). Short
stay cases (<1 day) were excluded unless they had died,
as these cases are generally due to transfer between
hospitals and lead to duplicate counting of cases.
For the calculation of incidences, the size of the
German population was estimated as 82534786 based
on the number of persons registered in each state on
31 December 2003 (data reported to the RKI by the
16 State Statistical Offices).
RESULTS
Comparison of datasets
The distribution of age and sex was similar in the
two datasets. Under exclusion of cases with no
information on serogroup from the RKI dataset






















Fig. Number of cases reported to Robert Koch Institute
(&) and tested at the National Reference Centre for
Meningococci (%) according to serogroup, Germany, 2003.
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but significantly (P=0.03, x2), due to a higher
proportion of serogroup B disease and a lower pro-
portion of serogroup C disease reported to the RKI,
as well as the absence of non-typable and serogroup
A strains in the NRZM dataset (three cases in RKI
dataset).
The geographical distribution of cases according to
federal state also differed significantly between the
two data sources (P=0.005, Kolmogorov-Smirnoff ).
Compared to the distribution of cases reported to
the national surveillance system, the NRZM received
specimens more frequently from Bavaria and sur-
rounding states.
CRA
The observed IMD incidence based on RKI data was
0.9 cases/100 000 inhabitants and based on NRZM
data, 0.7 cases/100 000 inhabitants. A total of 507
IMD cases were identified as common to both the
RKI and NRZM datasets, with 272 and 58 cases
unique to the RKI and NRZM datasets respectively.
Thus, 872 cases (95% CI 858–886) of IMD were
estimated to have occurred in Germany in 2003
by CRA, corresponding to an IMD incidence of
1.1/100 000 inhabitants (Table). The estimated sensi-
tivity of ascertainment was 65% for NRZM and 89%
for RKI.
Stratified analysis
The sensitivity of ascertainment was similar in all age
groups in the RKI system but slightly lower in adults
compared to children and adolescents in the NRZM
(Table). Estimated incidence was highest for children
aged <5 years at 8.8 cases/100 000 inhabitants and
lowest in adults (Table). The sum of the number
of estimated cases in all age strata (876 cases, plus
two cases excluded from this analysis due to missing
data) was only slightly higher than the overall CRA
estimate.
While the sensitivity of ascertainment was signifi-
cantly higher for serogroup C (83%) than for sero-
group B cases (72%) at the NRZM but not the RKI,
the sum of the estimated number of serogroup B and
C cases (704) differed only minimally from the total
number of estimated serogroup B and C cases (700).
The estimated IMD incidence in Bavaria and sur-
rounding states combined was 0.9/100 000 inhabitants
and in the remaining states situated farther from
the NRZM, 1.2/100 000 inhabitants (Table). While
the estimated sensitivity of ascertainment differed
only slightly between these two strata for RKI, this
difference was marked for NRZM, with a sensitivity
of 71% for Bavaria and surrounding states and 59%
for the remaining states. The sum of the estimated
number of cases in the two regions (869, plus five
cases excluded from this analysis due to missing
data) was also almost identical to the overall CRA
estimate.
A total of 53 IMD deaths were identified as
common to both the RKI and NRZM datasets, with
six cases and 13 cases unique to the NRZM and RKI
datasets respectively. Thus, 77 IMD deaths (95% CI
75–79) were estimated to have occurred by CRA. The
sensitivity of ascertainment was higher for deaths
(77%) than non-deaths (63%) at the NRZM but not
the RKI (Table). The estimated mortality was thus
0.1/100 000 inhabitants and the estimated case-fatality
rate was 8.8% (77/872). The sum of the estimated
number of deaths and non-deaths (877) was only
marginally higher than the overall estimate.
Hospital discharge statistics
According to hospital discharge data, 950 cases
(1.2/100 000 inhabitants) were dischargedwith ICD-10
code A39 in Germany in 2003. Among these were 85
deaths (case-fatality rate 8.9%).
DISCUSSION
CRA results suggest that the incidence of IMD
in Germany is indeed low at 1.1 cases/100 000
inhabitants. The degree of ascertainment of IMD
cases was higher in the RKI (89.4%) compared to the
NRZM source (64.8%), reflecting the high number of
cases unique to RKI. The incidence of IMD in 2003
estimated by CRA was 11.9% higher than that
calculated from cases reported to RKI alone.
CRA using only two sources tends to underestimate
the true number of cases in the population if sources
are positively dependent [17]. In addition, testing for
independence is only possible with more than two
sources ; unfortunately, however, a case-based third
data source was not available in Germany. Some
degree of positive dependence between the NRZM
and the statutory surveillance system is probable, as
laboratories sufficiently motivated to send isolates to
the NRZM for further testing may also be more likely
to report cases to the statutory surveillance system
and vice versa [20]. According to Brenner [18], the
very fact that more severe cases are often less likely to
660 A. Schrauder and others
























All cases 779 565 507 31 872 (858–886) 89 (88–91) 65 (64–66) 1.1
Stratified by age*
Cases <5 yr 293 215 194 11 328 (320–337) 89 (87–92) 66 (64–67) 8.8
Cases 5–19 yr 313 232 210 11 349 (341–358) 90 (88–92) 66 (65–68) 2.6
Cases >19 yr 173 116 103 9 199 (191–207) 87 (84–91) 58 (56–61) 0.3
Stratified by serogroup#
Serogroup C 185 170 156 3 205 (201–209) 90 (89–92) 83 (82–85) 0.3
Serogroup B 443 365 323 16 504 (494–514) 88 (86–90) 72 (71–74) 0.6
Serogroup B or C 628 534 479 17 704 (694–713) 89 (88–91) 76 (75–77) 0.9
Stratified by region$
Bavaria and six surrounding
states
341 270 245 10 380 (372–387) 90 (88–92) 71 (70–73) 0.9
Nine non-surrounding states 438 290 262 19 489 (477–500) 90 (88–92) 59 (58–61) 1.2
Stratified by vital status
Deaths 66 59 53 2 77 (74–80) 86 (83–89) 77 (74–80) 0.1
Non-deaths 714 507 455 30 800 (785–814) 89 (88–91) 63 (62–65) 1.0
RKI, Robert Koch-Institute ; NRZM, National Reference Centre for Meningococci (located at the Institute for Hygiene and Microbiology at the University of Würzburg,
Bavaria) ; CI, confidence interval.
* Two cases from the NRZM had to be excluded from this analysis due to missing data on age.
# Includes only cases with serogroup B or C.



























be missed by different sources than less severe cases
often leads to positive dependence of ascertainment.
Stratification for factors which may have contributed
to dependency between the sources (as well as to
heterogeneity of capture, see below) only marginally
increased the CRA estimate of IMD incidence. Thus,
while it is possible that the CRA estimate of IMD
incidence is still an underestimate, it is closer to the
true IMD incidence in Germany than an estimate
based solely on statutory surveillance data.
IMD incidence estimated according to the number
of cases classified as ICD-10 A39 in the hospital
discharge statistics was slightly higher than our
CRA estimate. However, ICD-10 code A39 includes
a variety of different diagnoses associated with
meningococcal disease. While those cases classified as
A39.0, A39.1 and A39.2 probably fulfilled the case
definition applied in our study (829 cases), a certain
proportion of the remaining cases may not have been
acute or invasive. Nonetheless, these data also suggest
that there may be some degree of underreporting of
IMD to the statutory surveillance system in Germany.
A rigorous case definition based on laboratory
confirmation or clinical compatibility with an epidemi-
ological link to a laboratory-confirmed case was
applied in order to ensure that all identified cases in
both systems were true cases, thus minimizing the risk
of misclassification. Only four cases from the RKI
system were not laboratory confirmed, but these were
included so as not to preclude possible matching with
a NRZM case, which indeed occurred in one of these
cases. A small degree of misclassification of the
matching variables cannot be entirely ruled out. For
instance, it is possible that the RKI cases with
serogroup A were wrongly diagnosed due to the use of
a latex agglutination test that differentiates only
between serogroup B and serogroups A, C, Y and
W135. Concerning the classification of deaths, routine
quality assurance at the RKI since 2004 has consist-
ently confirmed notified deaths as true deaths
(W. Hellenbrand, personal communication); thus, the
validity of the classification seems high. As a combi-
nation of several identifying variables was used,
the matching process can also be considered robust.
We were able to reliably identify a high proportion
of matching data records in the two sources.
Furthermore, it was possible to verify additional data-
record pairs identified as tentative matches by linking
personal data back to the anonymized records at
the NRZM and the responsible regional health
authority. This enabled verification of 57 of the 75
(76%) tentative matches identified by our matching
algorithm.
For the RKI source, the sensitivity of ascertain-
ment did not vary substantially according to age,
diagnosed serogroup or region (Table), suggesting
that these factors did not markedly influence the
probability of capture by the statutory surveillance
system [21, 22]. Furthermore, the sensitivity of the
RKI source was consistently higher than that of
the NRZM in all strata analysed, a constellation
that may also lead to an underestimate of total
incidence [14].
In contrast, the above factors did influence the
sensitivity of ascertainment by the NRZM: Adult
cases had a slightly lower probability of capture,
suggesting that peripheral laboratories were more
likely to submit samples from children and ado-
lescents for fine typing. Not unexpectedly, cases from
Bavaria – where the NRZM is located – and sur-
rounding states were also more likely to be captured
by the NRZM, probably reflecting a higher local
awareness. This finding suggests that informing
laboratories located farther from the NRZMmight be
useful. Cases with serogroup C were also more likely
to be captured by the NRZM. As serogroup C disease
has been observed to be more severe and have a
higher case-fatality rate in Germany [23], this may
reflect initiation of more detailed diagnosis at the
NRZM for more severe cases [8]. Submission to the
NRZM may also be related to awareness that sero-
group C disease is vaccine preventable, as the identi-
fication of clusters through fine typing in the past has
led to local vaccination campaigns [23]. The higher
sensitivity of ascertainment for IMD deaths com-
pared to the overall sensitivity also suggests referral to
the NRZM is more likely for cases with severe disease.
Although the probability of capturing a case should
not vary in CRA, variable catchability contributes
relatively little bias [24]. In our case, although
stratified analysis revealed that cases were more likely
to be captured by the NRZM than the RKI if they
were caused by serogroup C, if they were from states
surrounding the NRZM or if they had a fatal out-
come (trap fascination) [8, 24], for all cases the sum
of the stratified results was only minimally higher
than the overall CRA incidence estimate (Table).
Prior to this study, NRZM fine typing results
were only reported to the submitting laboratory.
Recognition that not all cases tested at the NRZM
were reported to the statutory surveillance system led
to the establishment of direct reporting of fine typing
662 A. Schrauder and others
results by the NRZM to the regional health offices
starting in November 2004, thereby establishing a
direct link between the two data systems. This has led
to an improvement in the quality of the statutory
surveillance data, but also means that the two systems
must be considered highly dependent in future, pre-
cluding further CRA.
Overall, our results suggest that Germany is indeed
a country with a low incidence of IMD compared to
other European countries [10]. The sensitivity of the
statutory surveillance system in Germany for the
ascertainment of IMD is high. Any underreporting
might be reduced by the implementation of an elec-
tronic reporting system for clinicians and laboratories
in Germany, as has been shown in Sweden [25].
However, this is not planned for the immediate
future. Possible reasons for low observed incidence
other than underreporting include under diagnosis
due antibiotic therapy prior to testing and lower
blood-culture rates than in other countries [26] ;
however, data on these factors is lacking. Finally, a
true low incidence may be in part explained by a lower
prevalence of major risk factors for transmission
of meningococci, e.g. less frequent day-care attend-
ance by infants and toddlers and less frequent habi-
tation by students in dormitories compared to other
European countries.
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